Literature DB >> 27650618

SDF-1 Expression is Associated with Poor Prognosis in Osteosarcoma.

Dangen Yu1, Fei Lv1, Jianhe Zhang1, Hongjie Li2.   

Abstract

BACKGROUND: Stromal cell-derived factor-1 (SDF-1) expression has been reported to be a predictor of poor clinical symptoms in certain types of cancer. Vascular endothelial growth factor (VEGF) is a well-known factor that mediates the micro-angiogenesis of solid tumors, and SDF-1 mediated expression of VEGF may promote tumor growth and metastasis, resulting in poor clinical outcome. Therefore, we explored the expression levels of SDF-1 and VEGF in patients with osteosarcoma in order to determine the association between their expression levels and unfavorable outcomes.
METHODS: A total of 54 patients with osteosarcoma were included in the current study. The protein expression levels of SDF-1 and VEGF were evaluated on immunohistochemical and immunofluorescence staining. The correlation between the expression levels of SDF-1 and VEGF and their association with clinical parameters were analyzed using the Pearson chi-square test and the Spearman-rho test. Univariate and multivariate Cox regression analyses were used to identify potential prognostic factors. The Kaplan-Meier method was employed to analyze overall survival. RESULT: Low SDF-1 and VEGF expression levels were detected in 20.4% (11 of 54) and 22.2% (12 of 54) of the patients with osteosarcoma, respectively; moderate expression was detected in 35.2% (19 of 54) and 37.0% (20 of 54) of the patients, respectively; and high expression was detected in 44.4% (24 of 54) and 40.7% (22 of 54) of the patients, respectively. Protein levels of both SDF-1 and VEGF were significantly associated with the histologic grade (p=0.004 and p=0.042 respectively), the presence of metastasis (p=0.009 and p=0.028 respectively), and Enneking staging (p<0.001 and p=0.003 respectively). The association between expression levels of SDF-1and VEGF had a significantly positive correlation (p<0.001and r=0.618). The expression levels of both SDF-1 and VEGF were significantly associated with shorter overall survival on univariate analysis; however, the association was significant for SDF-1 expression alone in the multivariate analysis (p=0.26, hazard ratio =2.640 [1.124-6.200]).
CONCLUSION: SDF-1 and VEGF expression levels were both significantly associated with osteosarcoma, and SDF-1 expression is a potential independent prognostic indicator in patients with osteosarcoma.
© 2016 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  SDF-1; VEGF; osteosarcoma; prognostic indicator; soft tissue sarcoma

Mesh:

Substances:

Year:  2016        PMID: 27650618

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  5 in total

1.  Comment on 'A meta-analysis of CXCL12 expression for cancer prognosis'.

Authors:  Zu-Bing Mei; Chun-Sheng Luo; Qing-Ming Wang; Wei Yang
Journal:  Br J Cancer       Date:  2018-01-04       Impact factor: 7.640

2.  Reply to 'Comment on 'A meta-analysis of CXCL12 expression for cancer prognosis".

Authors:  Alex Gordon-Weeks
Journal:  Br J Cancer       Date:  2018-01-04       Impact factor: 7.640

3.  Crude Fucoidan Extracts Impair Angiogenesis in Models Relevant for Bone Regeneration and Osteosarcoma via Reduction of VEGF and SDF-1.

Authors:  Fanlu Wang; Harald Schmidt; Dijana Pavleska; Thees Wermann; Andreas Seekamp; Sabine Fuchs
Journal:  Mar Drugs       Date:  2017-06-20       Impact factor: 5.118

4.  SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA.

Authors:  Xiaoyu Wang; Yuanjian Fang; Yunxiang Zhou; Xiaoming Guo; Ke Xu; Chenguang Li; Jianmin Zhang; Yuan Hong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-09       Impact factor: 5.555

5.  Influence of Fucoidan Extracts from Different Fucus Species on Adult Stem Cells and Molecular Mediators in In Vitro Models for Bone Formation and Vascularization.

Authors:  Fanlu Wang; Yuejun Xiao; Sandesh Neupane; Signe Helle Ptak; Ramona Römer; Junyu Xiong; Julia Ohmes; Andreas Seekamp; Xavier Fretté; Susanne Alban; Sabine Fuchs
Journal:  Mar Drugs       Date:  2021-03-29       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.